Under the terms of the agreement, Mammoth Biosciences will receive an upfront payment of USD 40 million, potential future payments of more than one billion USD upon successful achievement of certain research, development, and commercial milestones
Product candidates will be based on BioNTech’s proprietary mRNA technology and on Pfizer’s antigen technology. Clinical trials are expected to start in the second half of 2022
The transaction is expected to close in the first quarter of 2022
EMBER500RNA Prestain Loading Dye allows single-step denaturing, loading, and bright RNA staining on regular agarose gels
Biogen paid Ionis a US $ 60 million one-time upfront payment
It has also been granted permission to conduct trials for booster dose
BPZE1 is the most advanced next-generation pertussis vaccine currently in clinical development
Upon completion of successful human trials and regulatory approval, the joint venture's goal is to start delivering the second-generation vaccine in 2022 as soon as is practically possible
First emergency use authorization in the United States for a Covid-19 vaccine booster in adolescents 12 through 15 years of age
The Subject Expert Committee has recommended grant of permission to conduct Phase 3 trials under certain conditions
Subscribe To Our Newsletter & Stay Updated
